Copenhagen, Denmark, 23 August 2021. FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the first publication of preclinical data where the Company's compound FG001 is used as a photothermal therapy agent for treatment of cancer. The new feature of FG001 complements the surgical targeting and opens new opportunities for the realization of clinical and commercial potential of the Company's uPAR-targeting technology platform.
Link/Full details:
https://news.cision.com/fluoguide/r/publication-of-promising-preclinical-data-on-fg001s-effect-in-treatment-of-cancer,c3401276
Publication:
https://www.oncotarget.com/article/28013/pdf/
Link/Full details:
https://news.cision.com/fluoguide/r/publication-of-promising-preclinical-data-on-fg001s-effect-in-treatment-of-cancer,c3401276
Publication:
https://www.oncotarget.com/article/28013/pdf/
25/8 2021 17:57 iskh 0
96377 (PDF) Q2 2021 Regnskab og highlights for Fluoguide:
https://fluoguide.com/wp-content/uploads/FluoGuide-Q2-2021-report-Final.pdf
https://fluoguide.com/wp-content/uploads/FluoGuide-Q2-2021-report-Final.pdf
